Avantor® announces new j.t.baker® cell lysis solution and j.t.baker® endonuclease

Innovative solutions optimize the harvest process in gene therapy manufacturing sustainably and at scale radnor, pa. , july 1, 2024 /prnewswire/ -- avantor, inc. (nyse: avtr), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the launch of two innovative products that together sustainably optimize the gene therapy harvest process: j.t.baker® cell lysis solution and j.t.baker® endonuclease.
AVTR Ratings Summary
AVTR Quant Ranking